Shire gains a delayed FDA OK for ‘blockbuster’ dry eye drug lifitegrast
Nine months after the FDA handed Shire $SHPG a rejection for its dry eye drug lifitegrast, the biotech company says it’s bounced back with a delayed approval from the FDA. And now Shire will set out to see if it can achieve its earlier forecast of more than a billion dollars in annual sales.
Shire will be tackling a broad market including more than 16 million people who have been diagnosed with dry eye disease. The company plans to get started marketing the eye drop therapy in a few months, selling it as Xiidra.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.